Treatment of non-small cell lung cancer patients with performance status2 (PS2)

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 10-15

  Boukovinas, Ioannis ^a   Kosmidis, Paris ^b  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b HYGEIA HOSPITAL   (Greece)

Author keywords

Chemotherapy; Non small cell lung cancer; Performance status2 (PS2); Prognostic factor; Toxicity profile; Treatment

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; VINDESINE;

AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COMORBIDITY; DRUG MEGADOSE; ELECTROCORTICOGRAPHY; FEBRILE NEUTROPENIA; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 57649097449     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.05.016     Document Type: Review

References (49)

1. Parkin D.M., and Saxo A.J. Lung cancer: worldwide variation in occurrence and proportion attributable to tobacco use. Lung Cancer 9 Suppl. (1993) 1-16
2. Rankin E.M. Non-small cell lung cancer. In: Slevin M.L., and Staquet M.J. (Eds). Randomised trials in cancer: critical review (1986), Raven Press, New York 447-492
3. Silverberg E., Boring C.C., and Squires T.S. Cancer statistics. CA Cancer J Clin 40 9 (1990) 26
4. Squires T.S., and Tong T. Cancer statistics. CA Cancer J Clin 43 (1993) 7-26
5. Rudd R. Chemotherapy in the treatment of non-small cell lung cancer. Respir Dis Pract 7 (1991) 12-15
6. Lilenbaum R.C., Cashy J., Hensing T.A., Young S., and Cella D. Prevalence of poor performance status in lung cancer patients. J Thorac Oncol 3 (2008) 125-129
7. Karnofsky D.A., and Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod C.M. (Ed). Evaluation of chemotherapeutic agents (1949), Columbia University Press, New York, NY 199-205
8. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
9. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
10. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer Eastern Cooperative Oncology Group 1594. N Engl J Med 346 (2002) 92-98
11. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer Italian Lung Cancer Project. J Clin Oncol 20 (2002) 4285-4291
12. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95 (2003) 362-372
13. Buccheri G., Ferrigno D., and Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A (1996) 1135-1141
14. Radzikowska E., Glaz P., and Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20651 cases. Ann Oncol 13 (2002) 1087-1093
15. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65 (1980) 25-32
16. Albain K.S., Crowley J.J., LeBlanc M., and Livingston R.B. Survival determinants in extensive stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9 (1991) 1618-1626
17. Takigawa N., Segawa Y., Okahara M., Maeda Y., Takata I., Kataoka M., et al. Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. Lung Cancer 15 (1996) 67-77
18. Ando M., Ando Y., Sugiura S., Minami H., Saka H., Sakai S., et al. Prognostic factors for short-term survival in patients with stage IV non-small cell lung cancer. Jpn J Cancer Res 90 (1999) 249-253
19. Brundage M.D., Davies D., and Mackillop W.J. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 122 (2002) 1037-1057
20. Socinski M.A., Morris D.E., Masters G.A., and Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer American College of Chest Physicians. Chest 123 1 Suppl. (2003) 226S-243S
21. Jiroutek M., Johnson D., and Blum R. Prognostic factors in advanced non-small-cell lung cancer: analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc Am Soc Clin Oncol 17 (1998) 461 [Abstract 1774]
22. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetiyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17 (1999) 3188-3194
23. Sweeney C.J., Zhu J., Sandler A.B., Schiller J., Belani C.P., Langer C., et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer 92 (2001) 2639-2647
24. Crino L., Novello S., Migliorino M.R., Foggi P., Gridelli C., Galli L., et al. A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): impact of PS = 2 vs 0 or 1 and age >70 vs. <70 on chemotherapy outcome. Proc Am Soc Clin Oncol 21 (2002) 315a [Abstract 1258]
25. Gridelli C., Ardizzoni A., LeChevalier T., Manegold C., Perrone F., Thatchet N., et al. Treatment of advanced non-small-cell lung cancer patients with EGOG performance status 2: results of an European Experts Panel. Ann Oncol 15 March (3) (2004) 419-426
26. Soria J.C., Douillard J.Y., and Pujol J.L. Prognostic analysis of survival in the European randomized trial comparing navelbine (NVB) vs. navelbine cisplatin (NVB-P) vs. vindesine cisplatin (VDS-P). Proc Am Soc Clin Oncol 18 (1999) 491a
27. Kosmidis P., Mylonakis N., Nikolaides C., Kalophonos C., Samantas E., Boukovinas I., et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small lung cancer: a phase III randomized trial. J Clin Oncol 20 September (17) (2002) 3578-3585
28. Alberola V., Camps C., Provencio M., Isla D., Rosell R., Vadell C., et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21 (2003) 3207-3213
29. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21 (2003) 3909-3917
30. 2) plus carboplatin (AUC6) in advanced non-small-cell lung cancer: a multicenter randomized trial. Ann Oncol 11 July (7) (2000) 799-805
31. Langer C., Li S., Schiller J., Tester W., Rapoport B.L., and Johnson D.H. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 25 (2007) 418-423
32. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
33. Anderson H., Hopwood P., Stephens R.J., Thatcher N., Cottier B., Nicholson M., et al. Gemcitabine plus best supportive care (BSC) vs. in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome UK NSCLC Gemcitabine Group non-small cell lung cancer. Br J Cancer 83 (2000) 447-453
34. Perrone F., Di Maio M., Gallo C., and Gridelli C. Outcome of patients with a performance status 2 in the Multicenter Italian Lung Cancer in the Elderly Study (Miles). J Clin Oncol 22 December (24) (2004) 5018-5020
35. Ranson M., Davidson N., Nicholson M., Falk S., Carmichael J., Lopez P., et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92 July (13) (2000) 1074-1080
36. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
37. Lilenbaum R.C., Herndon J., List M., Desch C., Watson D., Holland J., et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21 1a (2002) [Abstract 2]
38. Kosmidis P.A., Dimopoulos M.A., Syrigos C., Nicolaides C., Aravantinos G., Boukovinas I., et al. Gemcitabine vs. gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and PS 2. A prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 23 (2004) 627 [Suppl; abstract 7058]
39. Hesketh P.J., Chansky K., Lau D.H., Crowley J., and Gandara D.R. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age 70 or with performance status (PS) 2 A SWOG phase II trial (S0027). J Clin Oncol 23 (2004) 627 [Suppl; abstract 7056]
40. Lilenbaum R., Rubin M., Samuel J., Boros L., Chidiac T., Seigel L., et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 23 (2004) 627 [Suppl; abstract 7057]
41. O'Brien M., and Oldham F. Paclitaxel poliglumex vs. gemcitabine or vinorelbine for the treatment of performance status 2 patients with chemotherapy-naive advanced non-small cell lung cancer: the STELLAR 4 phase III study. EJC Suppl 3 October (2) (2005) 324 [(plus oral) abstract 1122]
42. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21 June (12) (2003) 2237-2246
43. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 October (16) (2003) 2149-2158
44. Shepherd FA, Pereira J, Cuieleanu TE, Tan EH, Hirsch V, Thongprasert S et al., A randomized placebo-controlled trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22, no. 14s (July 15 supplement); 2004. p. 7022.
45. Zinner R., Govidan R., Wozniak A.J., Wade J.L., Belani C.P., Thienelt C.D., et al. Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP). Proc Am Soc Clin Oncol 22 14S (2004) 7082 (July 15 supplement)
46. Ervin T.J., and Toothaker S.R. Community practice experience with gefitinib (ZD1839) as treatment for patients with advanced non-small-cell lung cancer (NSCLC) within an expanded access clinical program. Proc Am Soc Clin Oncol 22 14S (2004) 7367 (July 15 supplement)
47. Gridelli C., Maione P., Castaldo V., and Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 89 (2003) 1827-1829
48. Argiris A., and Mittal N. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer 43 (2004) 317-322
49. Lilenbaum R., Axelrod R., Thomas S., Dowlati A., Seigel L., Albert D., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 26 (2008) 863-869